A new liquid biopsy approach developed by聽Johns Hopkins Kimmel Cancer Center investigators could revolutionize brain cancer detection by identifying circulating DNA fragments from tumors and immune cells in blood samples, potentially enabling earlier diagnosis.
Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools
Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, announces its achievement of ISO 9001:2015 certification. This internationally recognized standard demonstrates Nabsys' dedication to maintaining a robust and effective quality management system.
Researchers have uncovered multiple new genes and genetic pathways that could lead to repurposing hundreds of existing drugs for osteoarthritis, the most common form of arthritis.
How did horses become some of the greatest athletes in the animal kingdom? Researchers at Johns Hopkins Medicine may have found the answer, pinpointing a genetic mutation and evolutionary process that occurred millions of years ago, which appears to have optimized horses鈥� speeds and stamina.
鈥� RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥� Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥� This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥� Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development
鈥� Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥� Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies
A recent study has revealed that KIAA1199, a secreted protein produced by bone marrow cells, plays a crucial role in regulating both fat formation and overall energy metabolism. The protein's impact extends beyond bone remodeling, influencing glucose and lipid metabolism. Mice lacking KIAA1199 showed reduced fat mass, improved insulin sensitivity, and a decreased risk of obesity-related diseases. These findings suggest that targeting KIAA1199 could lead to new therapeutic strategies for combating metabolic disorders like obesity and type 2 diabetes.
Wren Laboratories, a leader in molecular diagnostics, is proud to announce that its breakthrough liquid biopsy test, PROSTest鈩�, has been approved by the New York State Department of Health Clinical Laboratory Evaluation Program (NYSDOH-CLEP).
Over 20 scientists from the Monell Chemical Senses Center will present their latest research at the 47th Association for Chemoreception Sciences annual conference, which covers the latest advances in the fields of taste, smell, and related chemical senses. Monell researchers are chairing and participating in oral presentation sessions as well as sharing close to 20 posters over three days. Several Monellians will also receive annual awards from AChemS for their research achievements, highlighted below.
Researchers at Mayo Clinic's Center for Individualized Medicine have discovered a rare genetic variant that can directly cause metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease.
A team of researchers has used advanced DNA sequencing to develop the most comprehensive atlas yet of genetic change through generations, laying the foundations for new insights into the roots of human disease and evolution.
An international team led by the University of California San Diego has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin.
ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13鈥�15, 2025, in New Orleans, LA.
A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder.
A newly identified subtype of Castleman disease will help diagnose and properly treat thousands of patients who have been caught between existing classification systems, marking the first major discovery of its kind in 45 years. "Oligocentric Castleman Disease" (OligoCD) has been found to be a distinct clinical entity, different from the two previously identified classifications of Castleman Disease. The findings, which redefine the understanding of this rare immune disorder that affects an estimated 4,300 to 5,200 Americans, are published this week in Blood Advances by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Capitalizing on the flexibility of tiny cells inside the body鈥檚 smallest blood vessels may be a powerful spinal cord repair strategy, new research suggests.
Physician-scientists from Cedars-Sinai Cancer will present research at the American Association for Cancer Research annual meeting April 25-30 in Chicago.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right